Organon (OGN) Treasury Shares (2021 - 2026)
Organon (OGN) posted quarterly Treasury Shares of $19.7 million for Q1 2026, up 82.18% year-over-year from $10.8 million in Q1 2025, and up 102.79% on a QoQ basis from $9.7 million in Q4 2025.
Organon (OGN) Treasury Shares (2021 - 2026) Analysis & Trends
Organon (OGN) has reported Treasury Shares for 6 consecutive years, with $19.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Treasury Shares rose 82.18% year-over-year to $19.7 million; the TTM figure through Mar 2026 stood at $19.7 million (up 82.18% YoY), while the FY2025 annual figure was $9.7 million, up 13.11% from the prior year.
- Treasury Shares came in at $19.7 million for Q1 2026 at Organon, up from $9.7 million in the prior quarter.
- The five-year high for Treasury Shares was $9.6 billion in Q1 2024, with the low at $120000.0 in Q1 2022.
- Average Treasury Shares over 5 years is $2.2 billion, with a median of $486.0 million recorded in 2022.
- Across the five-year window, Treasury Shares surged 6230733.33% in 2023 and tumbled 99.99% in 2025, its largest moves.
- Year by year, Treasury Shares stood at $486.0 million in 2022, then tumbled by 98.45% to $7.5 million in 2023, then sank by 85.08% to $1.1 million in 2024, then jumped by 766.73% to $9.7 million in 2025, then surged by 102.79% to $19.7 million in 2026.
- According to Business Quant data, Treasury Shares over the past three periods registered $19.7 million, $9.7 million, and $9.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 3.01 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 76.26 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 10.61 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 1.11 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 3.94 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | -47.00 Mn |
| 10 | Organon | 3.53 Bn | 2.41 Bn | 783.00 Mn | 19.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.70 Mn |
| Mar 31, 2026 | 19.70 Mn |
| Dec 31, 2025 | 9.72 Mn |
| Dec 31, 2025 | 9.72 Mn |
| Sep 30, 2025 | 9.66 Mn |
| Sep 30, 2025 | 9.66 Mn |
| Jun 30, 2025 | 1.01 Mn |
| Jun 30, 2025 | 1.01 Mn |
| Mar 31, 2025 | 10.82 Mn |
| Mar 31, 2025 | 10.82 Mn |
| Dec 31, 2024 | 1.12 Mn |
| Dec 31, 2024 | 1.12 Mn |
| Sep 30, 2024 | 1.12 Bn |
| Sep 30, 2024 | 1.12 Bn |
| Jun 30, 2024 | 8.65 Bn |
| Jun 30, 2024 | 8.65 Bn |
| Mar 31, 2024 | 9.62 Bn |
| Mar 31, 2024 | 9.62 Bn |
| Dec 31, 2023 | 7.51 Mn |
| Dec 31, 2023 | 7.51 Mn |